QuidelOrtho acquires TTP spin-out LEX Diagnostics to expand rapid point-of-care PCR portfolio

QuidelOrtho (NASDAQ:QDEL), a global powerhouse in in vitro diagnostics, has announced the acquisition of LEX Diagnostics.

A spin-out from the UK-based TTP Group, LEX Diagnostics is at the forefront of ultra-fast molecular testing, bridging the gap between the speed of rapid antigen tests and the accuracy of laboratory-grade PCR.

LEX Diagnostics was founded in 2020 through a TTP innovation program designed to commercialize breakthroughs in thermal control.

The company’s core technology enables "ultra-fast thermal cycling," allowing clinicians to achieve high-sensitivity molecular results in a fraction of the time required by traditional PCR machines.

The acquisition follows a major regulatory milestone for LEX Diagnostics.

In February 2026, the company received U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA-waived status for its flagship VELO system.

The VELO platform is designed to detect Flu A, Flu B, and COVID-19 directly from a swab sample.